Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Zimmermann

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Drug Design, Development and Therapy|November 26, 2015
Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan and Mowel after liver transplantationJohanna Vollmar, Maren Christina Bellmann, Felix Darstein, et al.
International Journal of Cardiology|August 6, 2018
Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial functionFrank P Schmidt, Tim Zimmermann, Till Wenz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 20, 2018
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patientsBenjamin Maasoumy, Peter Buggisch, Stefan Mauss, et al.
Drugs & Aging|August 8, 2018
Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C RegistryGeorg Dultz, Tobias Müller, Jörg Petersen, et al.
BMC Gastroenterology|August 5, 2015
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohortNiels Steinebrunner, Martin F Sprinzl, Tim Zimmermann, et al.
Journal of Clinical Gastroenterology|November 16, 2018
Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic EncephalopathyChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
BMC Cancer|April 18, 2015
Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinomaArndt Weinmann, Yvonne Alt, Sandra Koch, et al.
Transplantation|February 15, 2021
Ribavirin Improves NK Cell IFNγ Response During Sofosbuvir-based DAA Therapy in HCV-infected Liver Transplant RecipientsAkinbami Adenugba, Matthias Hornung, Kilian Weigand, et al.
Journal of Hepatology|June 28, 2011
Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivoJörn M Schattenberg, Tim Zimmermann, Marcus Wörns, et al.
European Journal of Internal Medicine|May 25, 2010
Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD)Tim Zimmermann, Maria Hoppe-Lotichius, Vuk Tripkovic, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Drug Design, Development and Therapy|November 26, 2015
Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan and Mowel after liver transplantationJohanna Vollmar, Maren Christina Bellmann, Felix Darstein, et al.
International Journal of Cardiology|August 6, 2018
Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial functionFrank P Schmidt, Tim Zimmermann, Till Wenz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 20, 2018
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patientsBenjamin Maasoumy, Peter Buggisch, Stefan Mauss, et al.
Drugs & Aging|August 8, 2018
Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C RegistryGeorg Dultz, Tobias Müller, Jörg Petersen, et al.
BMC Gastroenterology|August 5, 2015
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohortNiels Steinebrunner, Martin F Sprinzl, Tim Zimmermann, et al.
Journal of Clinical Gastroenterology|November 16, 2018
Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic EncephalopathyChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
BMC Cancer|April 18, 2015
Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinomaArndt Weinmann, Yvonne Alt, Sandra Koch, et al.
Transplantation|February 15, 2021
Ribavirin Improves NK Cell IFNγ Response During Sofosbuvir-based DAA Therapy in HCV-infected Liver Transplant RecipientsAkinbami Adenugba, Matthias Hornung, Kilian Weigand, et al.
Journal of Hepatology|June 28, 2011
Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivoJörn M Schattenberg, Tim Zimmermann, Marcus Wörns, et al.
European Journal of Internal Medicine|May 25, 2010
Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD)Tim Zimmermann, Maria Hoppe-Lotichius, Vuk Tripkovic, et al.
Pageof 9